Critical Medicines Act ‘must prioritise’ EU pharmaceutical manufacturing competitiveness
European Parliament's SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
List view / Grid view
European Parliament's SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
2 September 2025 | By FUJIFILM Wako Europe GmbH
Join this webinar to find out how RT-rt PCR is revolutionising sterility testing and discover a unique approach that provides reliable one-day results and enhanced sensitivity and detection capabilities.
Contracts to use a facility at Fujifilm’s North Carolina site as part of moves to onshore its manufacturing.
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
In this article, Miguel Angel Ortega Sánchez of ROIS explores how the industry is adapting to new delivery formats, device bottlenecks, and strategic partnership models — and why flexibility, compliance, and tech transfer agility are now critical to success.
15 August 2025 | By Bruker Microbiology & Infection Diagnostics
This webinar explores the benefits of accelerated microbial identification using MALDI-TOF in pharmaceutical contamination control strategies.
11 August 2025 | By Entegris
This webinar explores the design and implementation of pre use post sterilisation integrity test assemblies (PUPSIT) in sterile filtration processes to ensure regulatory compliance while minimising operational risk.
The scheme will provide more support and a streamlined application process to companies constructing new US facilities.
The novel approach could reduce the industry’s reliance on fossil fuels by offering a sustainable production alternative for pharmaceuticals.
New digital initiative will support the pharma company’s manufacturing and supply chain ambitions.
The proposed transaction means Just-Evotec Biologics’ Toulouse site would be used to develop and manufacture Sandoz biosimilars.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
The landmark regulation establishes a future where highly personalised treatments are part of routine care, says MHRA’s Chief Executive.
While a focus on accelerating access for innovative medicines has been welcomed, industry representatives caution that current system infrastructure could hinder the plans proposed by the UK Government.
Following their recent LinkedIn Live, Hexagon’s Adam Cross, Industry Director for Pharma and Life Sciences, reveals the state of data in pharmaceutical manufacturing, the opportunities available and how companies can ensure success and sustainable outcomes in their digitalisation journey.